Evidence map›Paper›PMID 28261517›Full record

ArticleJournal of pharmaceutics2017

Formulation and Evaluation of New Glimepiride Sublingual Tablets.

Wafa Al-Madhagi, Ahmed Abdulbari Albarakani, Abobakr Khaled Alhag, Zakaria Ahmed Saeed, Nahlah Mansour Noman, Khaldon Mohamed

Abstract read
In one paragraph

Article in Journal of pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wafa Al-MadhagiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen; Department of Pharmacy, Faculty of Medicine and Health Sciences, Yemeni Jordanian University, Sana'a, Yemen.ORCID 0000-0002-3409-1620
Ahmed Abdulbari AlbarakaniDepartment of Pharmacy, Faculty of Medicine and Health Sciences, Yemeni Jordanian University, Sana'a, Yemen.
Abobakr Khaled AlhagDepartment of Pharmacy, Faculty of Medicine and Health Sciences, Yemeni Jordanian University, Sana'a, Yemen.
Zakaria Ahmed SaeedDepartment of Pharmacy, Faculty of Medicine and Health Sciences, Yemeni Jordanian University, Sana'a, Yemen.
Nahlah Mansour NomanDepartment of Pharmacy, Faculty of Medicine and Health Sciences, Thamar University, Dhamar, Yemen.
Khaldon MohamedDepartment of Biomedical Science, Sana'a University, Sana'a, Yemen.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral mucosal delivery of drugs promotes rapid absorption and high bioavailability, with a subsequent immediate onset of pharmacological effect. However, many oral mucosal deliveries are compromised by the possibility of the patient swallowing the active substance before it has been released and absorbed locally into the systemic circulation. The aim of this research was to introduce a new glimepiride formula for sublingual administration and rapid drug absorption that can be used in an emergency. The new sublingual formulation was prepared after five trials to prepare the suitable formulation. Two accepted formulations of the new sublingual product were prepared, but one of them with disintegration time of 1.45 min and searching for preferred formulation, the binder, is changed with Flulac and starch slurry to prepare formula with disintegration time of 21 seconds that supports the aim of research to be used in an emergency. The five formulations were done, after adjusting to the binder as Flulac and aerosil with disintegration time of 21 seconds and accepted hardness as well as the weight variation. The assay of a new product (subglimepiride) is 103% which is a promising result, confirming that the formula succeeded. The new product (subglimepiride) is accepted in most quality control tests and it is ready for marketing.

Identifiers

PMID28261517
PMCPMC5316461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.